Incannex Assembles Clinical Advisory Board for PSX-001 Anxiety Drug
Event summary
- Incannex Healthcare formed a Clinical Advisory Board (CAB) on January 22, 2026, to advance its PSX-001 program for generalized anxiety disorder.
- The CAB includes three leading experts in psychiatry and neurobiology: C. Neill Epperson, Charles B. Nemeroff, and Alan F. Schatzberg.
- The board will advise on clinical trial design, endpoint selection, regulatory engagement, and strategic development for PSX-001.
- PSX-001 is an oral synthetic psilocybin treatment approved for Phase 2 clinical development.
The big picture
Incannex's formation of a high-profile Clinical Advisory Board underscores its strategic focus on advancing PSX-001 through rigorous clinical and regulatory pathways. The inclusion of leading academics and researchers in psychiatry and neurobiology signals a disciplined approach to drug development, aiming to strengthen the program's scientific rigor and patient-focused outcomes. This move comes as the biopharmaceutical industry increasingly leverages external expertise to navigate complex regulatory environments and enhance the credibility of novel therapies.
What we're watching
- Clinical Development
- How the CAB's guidance will influence the design and execution of PSX-001's Phase 2 trials.
- Regulatory Strategy
- Whether the CAB's expertise will accelerate regulatory approvals for PSX-001.
- Market Positioning
- The pace at which Incannex can differentiate PSX-001 in the competitive anxiety disorder treatment landscape.
Related topics